Celia Morgan

Has grant

Professor of Psychopharmacology

University of Exeter

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Celia Morgan is a faculty member in the Department of Psychopharmacology at the University of Exeter, United Kingdom. Her research primarily focuses on substance use disorders and the therapeutic potential of psychedelics and cannabinoids. Recent publications explore topics such as ketamine use disorder, the effects of cannabidiol on cannabis dependence, and the interplay between genetic predispositions and substance use in psychotic disorders.

Recent Grants

Grant: Open

MORE-KARE: A multi-centre investigation of increasing alcohol abstinence with ketamine-assisted psychological therapy in severe alcohol use disorder

Open Date: 2023-03-01

Close Date: 2026-11-30

Grant: Close

The Accommodation of Ontologically Challenging Psychedelic Experiences

Open Date: 2021-09-30

Close Date: 2025-06-24

Grant: Close

REFLECT: Understanding experiences of mental health in deprived coastal communities

Open Date: 2019-03-07

Close Date: 2020-03-07

Grant: Close

GCRF: Trauma and Adverse Childhood Experiences Springboard (TrACES)

Open Date: 2018-03-01

Close Date: 2019-02-28

Grant: Close

Reducing relapse in alcohol dependence with the NMDA receptor antagonist, ketamine

Open Date: 2015-06-07

Close Date: 2020-12-07

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Sally Adams

University of Birmingham

UNITED KINGDOM

View details

Tom Freeman

University of Bath

UNITED KINGDOM

View details

Lindsey Hines

University of Bath

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Celia Morgan

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options

Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychothera<u>p</u>y for methamphetamine use disorder (the KAPPA trial).

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.

Decreasing brain activity caused by acute administration of ketamine and alcohol - A randomized, controlled, observer-blinded experimental study.

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.

A Perspective on Psychedelics as Treatments for Addictions.

High potency cannabis use, mental health symptoms and cannabis dependence: Triangulating the evidence

Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms

Collaborators (3)

Sally Adams

Tom Freeman

Lindsey Hines

Make your next move.

Celia Morgan

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options

Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychothera&lt;u&gt;p&lt;/u&gt;y for methamphetamine use disorder (the KAPPA trial).

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.

Decreasing brain activity caused by acute administration of ketamine and alcohol - A randomized, controlled, observer-blinded experimental study.

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.

A Perspective on Psychedelics as Treatments for Addictions.

High potency cannabis use, mental health symptoms and cannabis dependence: Triangulating the evidence

Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms

Collaborators (3)

Sally Adams

Tom Freeman

Lindsey Hines

Make your next move.

Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychothera<u>p</u>y for methamphetamine use disorder (the KAPPA trial).